
Spine BioPharma Reports Phase 3 Topline Results for SB-01 in Chronic Low Back Pain
Spine BioPharma Releases Phase 3 Data for SB-01 in Chronic Low Back Pain: Trial Misses Primary Endpoint Amid Strong Safety and Subgroup Efficacy Signals Spine BioPharma, Inc., a clinical-stage biopharmaceutical…












